Latest Saturn V Capital Management LLC Stock Portfolio
Saturn V Capital Management LLC Performance:
2025 Q4: 23.87%YTD: 79.96%2024: -2.71%
Performance for 2025 Q4 is 23.87%, and YTD is 79.96%, and 2024 is -2.71%.
About Saturn V Capital Management LLC and 13F Hedge Fund Stock Holdings
On 2026-02-17, the fund reported it's updated stock portfolio. In the 13F Holdings report, Saturn V Capital Management LP reported an equity portfolio of $544.9 Millions as of 31 Dec, 2025.
The top stock holdings of Saturn V Capital Management LP are , AMLX, COGT. The fund has invested 16.1% of it's portfolio in ABIVAX SA and 10% of portfolio in AMYLYX PHARMACEUTICALS INC.
The fund managers got completely rid off CG ONCOLOGY INC, XENON PHARMACEUTICALS INC (XENE) and MERUS N V (MRUS) stocks. They significantly reduced their stock positions in CENTESSA PHARMACEUTICALS PLC (CNTA), COGENT BIOSCIENCES INC (COGT) and DYNE THERAPEUTICS INC (DYN). Saturn V Capital Management LP opened new stock positions in ALUMIS INC, X4 PHARMACEUTICALS INC (XFOR) and INVIVYD INC (ADGI). The fund showed a lot of confidence in some stocks as they added substantially to MONOPAR THERAPEUTICS INC (MNPR), OCULAR THERAPEUTIX INC (OCUL) and PHARVARIS N V (PHVS).
The top stock holdings of Saturn V Capital Management LP are , AMLX, COGT. The fund has invested 16.1% of it's portfolio in ABIVAX SA and 10% of portfolio in AMYLYX PHARMACEUTICALS INC.
The fund managers got completely rid off CG ONCOLOGY INC, XENON PHARMACEUTICALS INC (XENE) and MERUS N V (MRUS) stocks. They significantly reduced their stock positions in CENTESSA PHARMACEUTICALS PLC (CNTA), COGENT BIOSCIENCES INC (COGT) and DYNE THERAPEUTICS INC (DYN). Saturn V Capital Management LP opened new stock positions in ALUMIS INC, X4 PHARMACEUTICALS INC (XFOR) and INVIVYD INC (ADGI). The fund showed a lot of confidence in some stocks as they added substantially to MONOPAR THERAPEUTICS INC (MNPR), OCULAR THERAPEUTIX INC (OCUL) and PHARVARIS N V (PHVS).
Saturn V Capital Management LLC Annual Return Estimates Vs S&P 500
Our best estimate is that Saturn V Capital Management LP made a return of 23.87% in the last quarter. In trailing 12 months, it's portfolio return was 79.96%.
- Performance
- S&P 500
New Buys
| Ticker | $ Bought |
|---|---|
| alumis inc | 30,606,900 |
| x4 pharmaceuticals inc | 23,202,100 |
| invivyd inc | 19,106,400 |
| immix biopharma inc | 15,685,700 |
| oculis holding ag | 10,319,700 |
| inhibikase therapeutics inc | 7,906,440 |
| ovid therapeutics inc | 4,075,000 |
| inventiva sa | 1,316,720 |
New stocks bought by Saturn V Capital Management LLC
Additions
| Ticker | % Inc. |
|---|---|
| monopar therapeutics inc | 109 |
| ocular therapeutix inc | 30.67 |
| pharvaris n v | 28.62 |
| vaxcyte inc | 1.33 |
Additions to existing portfolio by Saturn V Capital Management LLC
Reductions
| Ticker | % Reduced |
|---|---|
| centessa pharmaceuticals plc | -61.51 |
| cogent biosciences inc | -39.9 |
| dyne therapeutics inc | -33.12 |
| celcuity inc | -33.08 |
| abivax sa | -18.98 |
| jazz pharmaceuticals plc | -17.48 |
| disc medicine inc | -12.46 |
| amylyx pharmaceuticals inc | -2.35 |
Saturn V Capital Management LLC reduced stake in above stock
Sold off
| Ticker | $ Sold |
|---|---|
| cg oncology inc | -23,358,200 |
| xenon pharmaceuticals inc | -20,223,600 |
| lenz therapeutics inc | -17,149,600 |
| merus n v | -17,336,300 |
| newamsterdam pharma company | -4,355,500 |
Saturn V Capital Management LLC got rid off the above stocks
Sector Distribution
Saturn V Capital Management LP has about 62.5% of it's holdings in Healthcare sector.
- Healthcare
- Others
| Sector | % |
|---|---|
| Healthcare | 62.5 |
| Others | 34 |
| 3.5 |
Market Cap. Distribution
Saturn V Capital Management LP has about 7.7% of it's portfolio invested in the large-cap and mega-cap stocks.
- UNALLOCATED
- MID-CAP
- SMALL-CAP
- MICRO-CAP
- LARGE-CAP
| Category | % |
|---|---|
| UNALLOCATED | 34 |
| MID-CAP | 28.2 |
| SMALL-CAP | 20.7 |
| MICRO-CAP | 9.3 |
| LARGE-CAP | 7.7 |
Stocks belong to which Index?
About 45.3% of the stocks held by Saturn V Capital Management LP either belong to S&P 500 or RUSSELL 2000 index.
- Others
- RUSSELL 2000
| Index | % |
|---|---|
| Others | 54.7 |
| RUSSELL 2000 | 45.3 |
Saturn V Capital Management LLC Holdings Map
This heatmap illustrates the top 50 positions within the fund's portfolio.
Current Stock Holdings of Saturn V Capital Management LLC
Saturn V Capital Management LP has 20 stocks in it's portfolio. About 76.5% of the portfolio is in top 10 stocks. AMLX proved to be the most loss making stock for the portfolio. was the most profitable stock for Saturn V Capital Management LP last quarter.
Last Reported on: 17 Feb, 2026| Ticker | Namesorted ascending | % Portfolio | Shares Held | $ Value | Type | % Change | Options | |
|---|---|---|---|---|---|---|---|---|
| ADGI | invivyd inc | 3.51 | 7,735,390 | 19,106,400 | new | |||
| AMLX | amylyx pharmaceuticals inc | 9.97 | 4,496,490 | 54,317,600 | reduced | -2.35 | ||
| CELC | celcuity inc | 5.80 | 317,095 | 31,627,100 | reduced | -33.08 | ||
| CNTA | centessa pharmaceuticals plc | 1.30 | 282,692 | 7,070,130 | reduced | -61.51 | ||
| COGT | cogent biosciences inc | 7.93 | 1,217,060 | 43,230,100 | reduced | -39.9 | ||
| DYN | dyne therapeutics inc | 6.42 | 1,788,620 | 34,985,300 | reduced | -33.12 | ||
| IKT | inhibikase therapeutics inc | 1.45 | 3,856,800 | 7,906,440 | new | |||
| IMMX | immix biopharma inc | 2.88 | 2,999,170 | 15,685,700 | new | |||
| IVA | inventiva sa | 0.24 | 283,166 | 1,316,720 | new | |||
| JAZZ | jazz pharmaceuticals plc | 7.74 | 248,070 | 42,171,900 | reduced | -17.48 | ||
| MNPR | monopar therapeutics inc | 3.90 | 325,701 | 21,268,300 | added | 109 | ||
| MRUS | merus n v | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| NAMS | newamsterdam pharma company | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| OCUL | ocular therapeutix inc | 3.35 | 1,504,880 | 18,269,200 | added | 30.67 | ||
| OVID | ovid therapeutics inc | 0.75 | 2,500,000 | 4,075,000 | new | |||
| PCVX | vaxcyte inc | 6.76 | 798,940 | 36,863,100 | added | 1.33 | ||
| PHVS | pharvaris n v | 5.81 | 1,140,030 | 31,635,900 | added | 28.62 | ||
| XENE | xenon pharmaceuticals inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| XFOR | x4 pharmaceuticals inc | 4.26 | 5,800,530 | 23,202,100 | new | |||
| abivax sa | 16.07 | 649,179 | 87,545,000 | reduced | -18.98 | |||